Business
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has the highest mortality rate among the systemic autoimmune diseasesDermatomyositis is a rare systemic autoimmune disease affecting ~80,000 individuals in the U.S., EU and Japan and has a five-year mortality rate as high as 70%Topline results from Phase 3 study of lenabasum for treatment of systemic sclerosis on target for summer of 2020 data readoutCorbus continues to be a pioneer in the development of transformative medicines that target the endocannabinoid system Norwood, MA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia.\n Summarized below are the abstract titles that have been selected for oral or poster presentations. The ACR abstracts are available online at the conference website. Information from the ACR presentations are under embargo until November 9, 2019 at 4:30 p.m. ET. Once the posters are made public, they will be available on the Company’s website in the Scientific Conferences section. Oral Presentations: Abstract #865: Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis SubjectsDate: Sunday, November 10, 2019Session: 3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868) (2:30 p.m. - 4:00 p.m. ET)Presentation Time: 3:00 p.m. - 3:15 p.m. ETPresenter: Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City and Principal Investigator of the Phase 2 study in systemic sclerosis Abstract #2843: Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) SubjectsDate: Tuesday, November 12, 2019Session: 5T113: Muscle Biology, Myositis & Myopathies II (28...